On Nov 05, major Wall Street analysts update their ratings for $UpStream Bio (UPB.US)$, with price targets ranging from $38 to $75.
J.P. Morgan analyst Tessa Romero initiates coverage with a buy rating, and sets the target price at $38.
TD Cowen analyst Yaron Werber initiates coverage with a buy rating.
William Blair analyst Matt Phipps initiates coverage with a buy rating.
Piper Sandler analyst Yasmeen Rahimi initiates coverage with a buy rating, and sets the target price at $75.
Furthermore, according to the comprehensive report, the opinions of $UpStream Bio (UPB.US)$'s main analysts recently are as follows:
Upstream Bio's primary asset, verekitug, a recombinant human IgG1 monoclonal antibody targeting the thymic stromal lymphopoietin receptor, is being developed to address severe asthma, chronic rhinosinusinitis with nasal polyps, and COPD. It is anticipated that verekitug will be the main catalyst for the company's stock performance in the medium to long term as its clinical profile advances.
The initiation of coverage on Upstream Bio with a positive outlook is based on the company's verekitug, which is regarded as a 'differentiated fast follower.' This is due to its higher potency and longer dosing intervals compared to Tezspire. Furthermore, the Phase 1 data have demonstrated 'rapid, deep, and sustained effects' on asthma biomarkers.
Here are the latest investment ratings and price targets for $UpStream Bio (UPB.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月5日，多家華爾街大行更新了$UpStream Bio (UPB.US)$的評級，目標價介於38美元至75美元。
摩根大通分析師Tessa Romero首次給予買入評級，目標價38美元。
TD Cowen分析師Yaron Werber首次給予買入評級。
威廉博萊分析師Matt Phipps首次給予買入評級。
派傑投資分析師Yasmeen Rahimi首次給予買入評級，目標價75美元。
此外，綜合報道，$UpStream Bio (UPB.US)$近期主要分析師觀點如下：
Upstream Bio的主要資產verekitug是一種重組人IgG1單克隆抗體，靶向胸腺基質淋巴瘤樣細胞因子受體，正在開發用於治療嚴重哮喘、慢性鼻竇炎伴鼻息肉和COPD。預計verekitug將成爲該公司中長期股票表現的主要催化劑，隨着臨床資料的進展。
對Upstream Bio進行積極展望的覆蓋啓動是基於該公司的verekitug，被視爲「不同尋常的快速追隨者」。這是因爲它相比Tezspire擁有更高的效力和更長的給藥間隔。此外，第1期數據已經證實了對哮喘生物標誌物的「迅速、深遠和持久的影響」。
以下爲今日4位分析師對$UpStream Bio (UPB.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
